683 results on '"Wei, Andrew"'
Search Results
2. How comparable are patient outcomes in the “real-world” with populations studied in pivotal AML trials?
3. Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts
4. Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers
5. Domestic lending and the pandemic: How does banks’ exposure to COVID-19 abroad affect their lending in the United States?
6. Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes
7. Gender and Professional Networks on Bank Boards
8. Venetoclax–based low intensity therapy in molecular failure of NPM1-mutated AML
9. Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine
10. A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome
11. Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG
12. Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study
13. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)
14. Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41
15. Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML
16. Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1st International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS)
17. Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes
18. Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cells
19. Acute myeloid leukaemia
20. Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia
21. Applying molecular measurable residual disease testing in acute myeloid leukaemia
22. Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial
23. Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial
24. Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine
25. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
26. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
27. Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial
28. Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status
29. Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies
30. It doesn’t stop at validation: patient reported outcome measures require ongoing and iterative development
31. Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial
32. Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL
33. Azacitidine Monotherapy in Patients With Treatment-Naïve Higher-risk Myelodysplastic Syndrome: A Systematic Literature Review and Meta-analysis
34. Do patients with haematological malignancies suffer financial burden? A cross-sectional study of patients seeking care through a publicly funded healthcare system
35. Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML).
36. Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia
37. An MRD-stratified pediatric protocol is as deliverable in adolescents and young adults as in children with ALL
38. Harnessing the benefits of available targeted therapies in acute myeloid leukaemia
39. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial
40. Sexism, household decisions, and the gender wage gap
41. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial
42. Towards precision medicine for AML
43. Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia
44. Laboratory quality assessment of candidate gene panel testing for acute myeloid leukaemia: a joint ALLG / RCPAQAP initiative
45. Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia
46. Outcomes and health care utilization of older patients with acute myeloid leukemia
47. Clinical MDR1 inhibitors enhance Smac-mimetic bioavailability to kill murine LSCs and improve survival in AML models
48. Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial
49. Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study
50. Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.